AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2001 SEP 5 - (NewsRx.com & NewsRx.net) --
by N.R. Saltmarsh, staff medical writer - A new Shigella flexneri 2a vaccine delivered intranasally could offer as much protection as live vaccines already studied in humans and warrants further consideration, say researchers working in the United States.
L.F. Fries and colleagues tested the vaccine, comprising native S. flexneri 2a lipopolysaccharide (LPS) complexed to meningococcal outer membrane proteins, in a dose-escalating series of two immunizations. Doses were 0.1, 0.4, 1.0, and 1.5 mg based on protein.
The vaccine elicited S. flexneri* 2a LPS-specific immunoglobulin A (IgA), IgG, and IgM antibody-secreting cells (ASCs) in a dose-responsive manner, noted Fries and team. At doses of 1.0 or 1.5 mg, subjects showed highly significant (P
Subjects also had dose-related serum antibody responses, including two- to fivefold rises in specific serum IgA and IgG titers and two- to threefold rises in IgM in the 1.0- and 1.5-mg groups. These elevated antibodies persisted through day 70.
The vaccine was well-tolerated and the most common reactions, rhinorrhea and nasal stuffiness, were self-limited and mild, reported Fries and coworkers ("Safety and immunogenicity of a proteosome-Shigella flexneri 2a lipopolysaccharide vaccine administered intranasally to healthy adults," Infection and ...